Greenwich LifeSciences, Inc. (GLSI)
NASDAQ: GLSI · Real-Time Price · USD
12.88
+0.03 (0.26%)
Nov 21, 2024, 1:56 PM EST - Market open
Greenwich LifeSciences Employees
As of December 31, 2023, Greenwich LifeSciences had 7 total employees, including 3 full-time and 4 part-time employees. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,499,333
Market Cap
169.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7 | 1 | 16.67% |
| Dec 31, 2022 | 6 | 0 | - |
| Dec 31, 2021 | 6 | 3 | 100.00% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Nutex Health | 800 |
| The Joint | 794 |
| Adaptimmune Therapeutics | 449 |
| Heron Therapeutics | 126 |
| Stereotaxis | 122 |
| KORU Medical Systems | 82 |
| Verastem | 73 |
| DiaMedica Therapeutics | 19 |
GLSI News
- 3 days ago - Greenwich LifeSciences Provides Update on Corporate Events - GlobeNewsWire
- 4 months ago - Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain - GlobeNewsWire
- 5 months ago - Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100 - Seeking Alpha
- 5 months ago - Greenwich LifeSciences Set to Join Russell 2000 Index Again - GlobeNewsWire
- 5 months ago - Greenwich LifeSciences Announces $2.5 Million Private Placement - GlobeNewsWire
- 9 months ago - Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025 - GlobeNewsWire
- 9 months ago - Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe - GlobeNewsWire
- 9 months ago - Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries - GlobeNewsWire